Monday, March 21, 2011

FDA Puts Early Alzheimer's Test on Hold

By Peggy Peck, Executive Editor, MedPage Today

The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early diagnosis of Alzheimer's disease -- until manufacturer Eli Lilly puts a training program in place, the company announced.

No comments:

Post a Comment